Compounds > carbamates
Page last updated: 2024-10-16

carbamates and Auricular Fibrillation

carbamates has been researched along with Auricular Fibrillation in 11 studies

Research Excerpts

ExcerptRelevanceReference
"Two patients experienced torsade de pointes (TdP): one patient without symptoms in dose group 3, and one patient requiring DC defibrillation in dose group 4."2.76Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously. ( Alings, M; Berggren, A; Bondarov, P; Edvardsson, N; Egstrup, K; Figatowski, W; Frison, L; Gaciong, Z; Hranai, M; Johansson, S; Király, C; Rónaszéki, A; Sereg, M, 2011)
" Maintenance dosing was for 9 days."2.76QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. ( Aunes-Jansson, M; Bergfeldt, L; Berggren, A; Duris, T; Edvardsson, N; Egstrup, K; Frison, L; Gullestad, L; Johansson, S; Kochmanski, M; Kuśnierz, B; Nielsen, T; Sawicki, S, 2011)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19902 (18.18)18.7374
1990's1 (9.09)18.2507
2000's1 (9.09)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mazaraki, I1
Gkouias, K1
Almpanis, G1
Kounis, NG1
Mazarakis, A1
Honda, H1
Gatanaga, H1
Matsumura, J1
Kamimura, M1
Goto, K1
Tsukada, K1
Honda, M1
Teruya, K1
Kikuchi, Y1
Oka, S1
Sicouri, S1
Carlsson, L2
Antzelevitch, C2
Burashnikov, A1
Zygmunt, AC1
Di Diego, JM1
Linhardt, G1
Vos, MA1
Rónaszéki, A1
Alings, M1
Egstrup, K2
Gaciong, Z1
Hranai, M1
Király, C1
Sereg, M1
Figatowski, W1
Bondarov, P1
Johansson, S2
Frison, L2
Edvardsson, N2
Berggren, A2
Bergfeldt, L1
Duris, T1
Gullestad, L1
Kochmanski, M1
Kuśnierz, B1
Nielsen, T1
Sawicki, S1
Aunes-Jansson, M1
Chabwine, JN1
Rossetti, AR1
Hirt, L1
Kuntzer, T1
Schluep, M1
Michel, P1
Démonet, JF1
du Pasquier, RA1
Vingerhoets, FG1
FINZI, CM1
BAZZANINI, G1
TOMASI, AM1
Cernusková, L1
Benes, L1
Csöllei, J1
Tumová, I1
Svec, P1
Singh, KP1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blind, Randomised, Placebo-controlled, Multicentre, Dose-escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation[NCT00915356]Phase 2228 participants (Actual)Interventional2009-05-31Completed
A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placeb[NCT00643448]Phase 265 participants (Actual)Interventional2008-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 10 Hours to 7 Days

(NCT00915356)
Timeframe: Conversion from AF to SR within 90 minutes from start of infusion

InterventionParticipants (Number)
AZD1305 Dose Group 10
AZD1305 Dose Group 22
AZD1305 Dose Group 35
AZD1305 Dose Group 41
Placebo0

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 31 Days - 3 Months

Subgroup analysis for patients with duration of current AF episode 31 days - 3 months. Number of patients converting from AF to SR. (NCT00915356)
Timeframe: Conversion from AF to SR within 90 minutes from start of infusion

InterventionParticipants (Number)
AZD1305 Dose Group 12
AZD1305 Dose Group 22
AZD1305 Dose Group 36
AZD1305 Dose Group 43
Placebo0

Conversion From AF to SR Within 90 Minutes From Start of Infusion in the Subgroup of Patients With Duration of Current AF Episode 8 Days - 30 Days.

Subgroup analysis for patients with duration of current AF episode 8 days - 30 days. Number of patients converting from AF to SR. (NCT00915356)
Timeframe: Conversion from AF to SR within 90 minutes from start of infusion

InterventionParticipants (Number)
AZD1305 Dose Group 10
AZD1305 Dose Group 24
AZD1305 Dose Group 36
AZD1305 Dose Group 42
Placebo0

Conversion of Atrial Fibrillation (AF) and Maintenance of Sinus Rhytm (SR)

Conversion of AF to SR with maintenance of SR maintained for at least 1 minute (NCT00915356)
Timeframe: Within 90 minutes from start of infusion

InterventionPercentage of patients converted to SR (Number)
AZD1305 Dose Group 17.7
AZD1305 Dose Group 217.8
AZD1305 Dose Group 337.8
AZD1305 Dose Group 450.0
Placebo0.0

Dose-response Relationship for QTcF Interval of AZD1305

QTcF-QT interval corrected for the RR interval (the time elapsing between two consecutive R waves in the electrocardiogram (ECG)) using the Fridericia formula.For each of 3 consecutive beats (5 consecutive beats if AF) a manual measurement, preferably in lead V2, of QTend intervals was done.The mean QT values of the 3 consecutive beats (5 consecutive beats if AF) were, together with RR intervals, date & time of the ECG, entered into the eCase Report Form (eCRF).The selected beats had to be marked with calipers and noted together with measured values and calculations on the print-out and signed (NCT00915356)
Timeframe: At any time post randomisation until end of Holter recording (18-24 hours post start of drug infusion).

Interventionms (Mean)
AZD1305 Dose Group 1461
AZD1305 Dose Group 2486
AZD1305 Dose Group 3490
AZD1305 Dose Group 4482
Placebo440

Heart Rhythm. Number of Participants With Early Relapse Into AF.

Early relapse into AF within 5 minutes from obtaining the defined criterion for conversion to SR (i.e.1 minute in SR). Patients never converted are not included in the analysis. (NCT00915356)
Timeframe: Within 5 minutes following investigational product (IP) induced conversion, or direct current (DC) cardioversion, of AF to SR

InterventionParticipants (Number)
AZD1305 Dose Group 11
AZD1305 Dose Group 21
AZD1305 Dose Group 32
AZD1305 Dose Group 40
Placebo1

Heart Rhythm. Number of Patients Remaining in SR up to 13 to 18 Days Following Study Drug Infusion.

Number of patients in SR at day 13-18 (NCT00915356)
Timeframe: During 13 to 18 days following study drug infusion

InterventionParticipants (Number)
AZD1305 Dose Group 114
AZD1305 Dose Group 223
AZD1305 Dose Group 325
AZD1305 Dose Group 47
Placebo22

Heart Rhythm. Number of Patients Remaining in SR up to 24 h Following Start of Study Drug Infusion

(NCT00915356)
Timeframe: During 24 hours following start of study drug infusion

InterventionParticipants (Number)
AZD1305 Dose Group 123
AZD1305 Dose Group 234
AZD1305 Dose Group 336
AZD1305 Dose Group 410
Placebo33

Maximal Observed Plasma Concentration of AZD1305

Plasma concentration of AZD1305 (NCT00915356)
Timeframe: Up to 24 hours following start of study drug infusion

Interventionmol/L (Median)
AZD1305 Dose Group 10.521
AZD1305 Dose Group 21.28
AZD1305 Dose Group 31.39
AZD1305 Dose Group 41.69

Percentage of Patients, Discharged Within 6 h (QTcF ≤500 ms) After Start of Infusion

Percentage, with 95% confidence interval, of patients with QTcF≤500 ms six hours following start of study drug infusion (NCT00915356)
Timeframe: Six hours following start of study drug infusion

InterventionPercent of participants (Number)
AZD1305 Dose Group 1100.0
AZD1305 Dose Group 295.5
AZD1305 Dose Group 391.1
AZD1305 Dose Group 4100.0
Placebo100.0

Wide QRS Tachycardias

Number of patients with wide QRS tachycardias, determined as significant arrhythmias by an Adjudication Committee (AC). The AC analysed and classified the occurrence of significant arrhythmias (other than AF or AFl) and pauses based on the 12-lead Holter reports. All pauses (≥3 sec) and all wide QRS complex tachycardias (≥3 beats, QRS ≥120 ms, and ≥120 bpm). (NCT00915356)
Timeframe: From start of study drug infusion until discharge from hospital on study day 2.

InterventionParticipants (Number)
AZD1305 Dose Group 14
AZD1305 Dose Group 215
AZD1305 Dose Group 316
AZD1305 Dose Group 42
Placebo7

Adverse Events (AE)

Number of patients who had at least one AE according to the definition in the study protocol (NCT00643448)
Timeframe: During treatment days 2-10

InterventionParticipants (Number)
AZD1305 Group A and AZD1305 Group B22
Placebo13

Compliance With Trans Telephonic Monitoring (TTM)

Percentage of twice daily TTM recordings (individual compliance) transmitted and available for analysis (NCT00643448)
Timeframe: During treatment days 1-10

InterventionPercentage of recordings analysed (Mean)
AZD1305 Group A97.4
AZD1305 Group B96.4
Placebo98.3

Estimated Cmax (Maximum Plasma Concentration) (PK Modeling) at Steady-state

Population PK model parameter estimates derived from plasma concentrations of AZD1305 (NCT00643448)
Timeframe: During treatment days 1-10

Interventionμmol/L (Mean)
AZD1305 Group A0.41
AZD1305 Group B0.45

Maximum QTcF

Maximum of all QTcF values obtained for any given patient from randomisation until the intended end of the study drug period, day 10. (NCT00643448)
Timeframe: During treatment days 2-10

Interventionms (Mean)
AZD1305 Group A and AZD1305 Group B461
Placebo427

Trials

2 trials available for carbamates and Auricular Fibrillation

ArticleYear
Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:8

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Dose-Res

2011
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Jun-01, Volume: 11, Issue:3

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Delayed-Action

2011

Other Studies

9 other studies available for carbamates and Auricular Fibrillation

ArticleYear
Carbamate skin contact-induced atrial fibrillation: toxicity or hypersensitivity?
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: Atrial Fibrillation; Carbamates; Humans; Hypersensitivity; Insecticides; Male; Methomyl; Middle Aged

2013
Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:6

    Topics: Adult; Anti-HIV Agents; Anticoagulants; Atrial Fibrillation; Carbamates; Drug Interactions; Furans;

2009
Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 334, Issue:1

    Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Comp

2010
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
    Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1

    Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo C

2010
The quest for an anti-arrhythmic drug against atrial fibrillation that combines efficacy with safety.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2010, Volume: 12, Issue:7

    Topics: Action Potentials; Animals; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Cells, Cultured;

2010
[Neurology].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai

2012
[COMPLEX CARDIAC ARRYTHMIAS IN THE COURSE OF ACUTE INTOXICATION DUE TO FUNGICIDE ACETYLCHOLINESTERASE INHIBITORS].
    Minerva medica, 1964, Mar-07, Volume: 55

    Topics: Adolescent; Adrenal Cortex Hormones; Agricultural Workers' Diseases; Arrhythmias, Cardiac; Atrial Fi

1964
Carbamate analogues of tocainide.
    Die Pharmazie, 1994, Volume: 49, Issue:9

    Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Carbamates; C

1994
Quinidine like activity of a new central depressant 2-hydroxy-2-phenyl-ethyl carbamate (styramate).
    Archives internationales de pharmacodynamie et de therapie, 1965, Volume: 157, Issue:2

    Topics: Acetylcholine; Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation

1965